The Bundeskartellamt has discontinued its proceedings examining the takeover of JenaValve Technology Inc. (in the following JenaValve) by Edwards Lifesciences Corporation (in the following Edwards), which was notified in September 2024. The proposed transaction was not subject to notification under merger control. The Bundeskartellamt’s examination has shown that the national notification thresholds were not met in this case. The transaction could have been subject to merger control in Germany under the so-called transaction value threshold as the value of the consideration for the takeover exceeded 400 million euros. However, another requirement for a transaction to be notifiable under the value threshold is that the target company already has substantial operations in Germany at the time of the acquisition. The investigations have shown that this was not the case for JenaValve. As a consequence, the Bundeskartellamt discontinued its proceedings.



JenaValve produces a new type of heart valve to treat patients with aortic regurgitation (AR). Edwards is a global leader in medical innovations for structural heart disease.

German Authority Halts JenaValve-Edwards Merger Review

The Bundeskartellamt, Germany's competition authority, has officially discontinued its proceedings regarding the proposed acquisition of JenaValve Technology Inc. by Edwards Lifesciences Corporation. This decision follows the notification of the merger in September 2024.

 Upon review, the Bundeskartellamt found that the transaction did not meet the national notification thresholds required for merger control. Although the value of the proposed acquisition exceeded 400 million euros, which could have triggered scrutiny under the transaction value threshold, the authority determined that JenaValve did not have substantial operations in Germany at the time of the acquisition.

 JenaValve specializes in developing innovative heart valves aimed at treating aortic regurgitation, while Edwards is recognized as a global leader in medical innovations for structural heart disease. The lack of substantial operations in Germany by JenaValve was a critical factor in the authority's decision to discontinue the merger proceedings.



German Authority Halts JenaValve-Edwards Merger Review

The German competition authority has ended its investigation into the merger between JenaValve Technology and Edwards Lifesciences, determining that the deal did not meet the necessary notification thresholds.